Carla Jorquera-Cordero
Overview
Explore the profile of Carla Jorquera-Cordero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muenzebrock K, Ho F, Pontes A, Jorquera-Cordero C, Utomo L, Garcia J, et al.
Pharmaceutics
. 2024 Apr;
16(4).
PMID: 38675100
Chronic lower back pain caused by intervertebral disc degeneration and osteoarthritis (OA) are highly prevalent chronic diseases. Although pain management and surgery can alleviate symptoms, no disease-modifying treatments are available....
2.
de Carvalho T, Lara P, Jorquera-Cordero C, Aragao C, Oliveira A, Garcia V, et al.
Biomed Pharmacother
. 2023 Oct;
168:115663.
PMID: 37832408
Colorectal cancer is still unmanageable despite advances in target therapy. However, extracellular vesicles (EVs) have shown potential in nanomedicine as drug delivery systems, especially for modulating the immune cells in...
3.
de Araujo Junior R, Lira G, Schomann T, Cavalcante R, Vilar N, de Paula R, et al.
Transl Oncol
. 2023 Mar;
31:101647.
PMID: 36857852
Tumour-associated macrophages (TAMs) often promote cancer progression through immunosuppression in the tumour microenvironment (TME). However, the signalling pathways crosstalk responsible for this mechanism remain unclear. The aim of our study...
4.
Garcia-Couce J, Schomann T, Chung C, Que I, Jorquera-Cordero C, Fuentes G, et al.
Gels
. 2022 Aug;
8(8).
PMID: 36005089
The intra-articular administration of drugs has attracted great interest in recent decades for the treatment of osteoarthritis. The use of modified drugs has also attracted interest in recent years because...
5.
Jorquera-Cordero C, Lara P, Cruz L, Schomann T, van Hofslot A, de Carvalho T, et al.
Pharmaceutics
. 2022 May;
14(5).
PMID: 35631654
One of the main reasons for cancer's low clinical response to chemotherapeutics is the highly immunosuppressive tumor microenvironment (TME). Tumor-ass ociated M2 macrophages (M2-TAMs) orchestrate the immunosuppression, which favors tumor...
6.
Campos Y, Fuentes G, Almirall A, Que I, Schomann T, Chung C, et al.
Pharmaceutics
. 2022 Feb;
14(2).
PMID: 35214015
Cartilage diseases currently affect a high percentage of the world's population. Almost all of these diseases, such as osteoarthritis (OA), cause inflammation of this soft tissue. However, this could be...
7.
Lara P, Huis In t Veld R, Jorquera-Cordero C, Chan A, Ossendorp F, Cruz L
Pharmaceutics
. 2021 Oct;
13(10).
PMID: 34683840
Photodynamic therapy (PDT) is a promising and clinically approved method for the treatment of cancer. However, the efficacy of PDT is often limited by the poor selectivity and distribution of...
8.
Lara P, Palma-Florez S, Salas-Huenuleo E, Polakovicova I, Guerrero S, Lobos-Gonzalez L, et al.
J Nanobiotechnology
. 2020 Jan;
18(1):20.
PMID: 31973696
Background: Extracellular vesicles (EVs) have shown great potential for targeted therapy, as they have a natural ability to pass through biological barriers and, depending on their origin, can preferentially accumulate...
9.
Valenzuela-Valderrama M, Cerda-Opazo P, Backert S, Gonzalez M, Carrasco-Veliz N, Jorquera-Cordero C, et al.
Cancers (Basel)
. 2019 Jun;
11(6).
PMID: 31185594
Chronic infection increases the risk of gastric cancer and induction of hypoxia-induced factor (HIF), which is frequently associated with the development and progression of several types of cancer. We recently...